Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
CONTEXT: Glucokinase plays a key role in glucose homeostasis. Glucokinase activators can lower glucose levels in both animal and human type 2 diabetes, but their mechanism of action has never been explored in humans. OBJECTIVE: The objective of the study was to investigate the effects of the glucokinase activator piragliatin (RO4389620) on β-cell function and glucose fluxes in both fasting and fed (oral glucose tolerance test) states in patients with type 2 diabetes. DESIGN: This was a phase Ib randomized, double-blind, placebo-controlled crossover trial of two (25 and 100 mg) doses of piragliatin. SETTING: This study was conducted at a clinical research center. PATIENTS: Patients included 15 volunteer ambulatory patients with mild type 2 diabetes. INTERVENTIONS: Interventions included three 10-h (-300' to +300') studies, with an interval of at least 14 d. Administration of a single dose of placebo or piragliatin 25 mg or piragliatin 100 mg at -120'. Oral glucose tolerance test (at 0') with dual (iv and oral routes) tracer dilution technique was conducted. MAIN OUTCOME MEASURES: The primary measure was plasma glucose concentration. The secondary measure was model assessed β-cell function and tracer-determined glucose fluxes. RESULTS: Piragliatin caused a dose-dependent reduction of glucose levels in both fasting and fed states (P < 0.01). In the fasting state, piragliatin caused a dose-dependent increase in β-cell function, a fall in endogenous glucose output, and a rise in glucose use (all P < 0.01). In the fed state, the primary effects of piragliatin were on β-cell function (P < 0.01). CONCLUSIONS: The glucokinase activator piragliatin has an acute glucose-lowering action in patients with mild type 2 diabetes, mainly mediated through a generalized enhancement of β-cell function and through fasting restricted changes in glucose turnover.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
Wilson, J. E. (2003) · Journal of Experimental Biology · doi:10.1242/jeb.00241 · Cited by 1,085 · cited 1×
“Glucokinase (GK) is one of a family of isoenzymes that catalyze the metabolism of glucose to glucose-6phosphate (1, 2).”
BackgroundDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 4×
“Variations of the order of magnitude we observed at the higher piragliatin dose should be quite effective in restraining hepatic glucose production (19, 20).”
BackgroundMethodInfluentialSelf-citationDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · cited 1×
“This feature is shared by some (24, 31, 32) but not all (33) recently introduced antidiabetic agents, when used in chronic treatment.”
BackgroundMolecular Physiology of Mammalian Glucokinase
Iynedjian, P. B. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8322-9 · Cited by 365
Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans
Bonadonna, R. C., Groop, L. C., Zych, K., Shank, M., & DeFronzo, R. A. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.259.5.e736 · Cited by 149 · cited 4×
“Variations of the order of magnitude we observed at the higher piragliatin dose should be quite effective in restraining hepatic glucose production (19, 20).”
BackgroundMethodInfluentialSelf-citationBasu, A., Dalla Man, C., Basu, R., Toffolo, G., Cobelli, C., & Rizza, R. A. (2009) · Diabetes Care · doi:10.2337/dc08-1826 · Cited by 129 · cited 1×
“Glucose tolerance, however, is determined by not only the total amount of glucose that enters and leaves the circulation but also the timing of and imbalances between these two processes (36).”
BackgroundCharacterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72 · cited 1×
“Under similar experimental conditions, only iv glucagon-like peptide-1 was shown to improve both controls of insulin secretion (35).”
MethodAvogaro, A., Toffolo, G., Valerio, A., & Cobelli, C. (1996) · Diabetes · doi:10.2337/diabetes.45.10.1373 · Cited by 55
Self-citation
Cited by
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., Zeng, J., Wang, G., Zhao, W., Zhang, Q., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30105-0 · Cited by 96
Doliba, N. M., Qin, W., Najafi, H., Liu, C., Buettger, C. W., Sotiris, J., Collins, H. W., Li, C., Stanley, C. A., Wilson, D. F., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00218.2011 · Cited by 96
Self-citationA comprehensive map of human glucokinase variant activity
Gersing, S., Cagiada, M., Gebbia, M., Gjesing, A. P., Coté, A. G., Seesankar, G., Li, R., Tabet, D., Weile, J., Stein, A., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02935-8 · Cited by 55
Metadata
- Authors
- Bonadonna, R. C., Heise, T., Arbet-Engels, C., Kapitza, C., Avogaro, A., Grimsby, J., Zhi, J., Grippo, J. F., & Balena, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-11
- Volume
- 95
- Issue
- 11
- Pages
- 5028-5036
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2013481385
- Cited by
- 141
- References
- 9
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.